Skip to main content

Table 4 Plasma lenalidomide pharmacokinetic (PK) parameters when administered alone or in combination with dexamethasone (PK cohort, n = 11)

From: A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

PK parametera

Day 1

Day 7: lenalidomide alone

Day 8: lenalidomide plus low-dose dexamethasone

(n = 11)

(n = 10)

(n = 10)

Tmax (h)

0.93 (0.50–3.17)

1.50 (0.50–3.08)

1.00 (0.50–2.98)

Cmax (ng/ml)

574 (28.3)

478 (19.3)

494 (19.9)

AUCt (h•ng/ml)

2323 (40.1)

1963 (36.6)

2093 (41.2)

AUC∞ (h•ng/ml)

2403 (41.2)

2141 (45.4)

2162 (42.6)

t1/2 (h)

3.34 (41.9)

2.79 (32.6)

3.08 (46.8)

CL/F (ml/min)

173 (41.2)

195 (45.4)

193 (42.6)

RAC (Cmax)

NA

0.84 (29.2)

NA

RAC (AUCÏ„)

NA

0.89 (17.9)

NA

  1. aGeometric mean (geometric coefficient of variation %) data are presented for all parameters except Tmax for which median (range) data are presented.
  2. Abbreviations: AUC Area under the plasma concentration–time curve, AUC ∞ AUC from time 0 to infinity, CL/F Apparent total plasma clearance, C max Maximum observed plasma concentration, NA Not applicable, RAC (AUC τ ) Accumulation ratio between Days 1 and 7 based on AUC, RAC (C max ) Accumulation ratio between Days 1 and 7 based on Cmax, t 1/2 Terminal phase half-life, T max Time to Cmax.